Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy

被引:76
作者
Ranieri, JM
Wagner, JD
Azuaje, R
Davidson, D
Wenck, S
Fyffe, J
Coleman, JJ
机构
[1] Indiana Univ, Sch Med, Dept Surg Plast & Reconstruct Surg, Indianapolis, IN USA
[2] Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN USA
[3] Indiana Univ, Sch Med, Dept Med Biostat, Indianapolis, IN USA
关键词
melanoma; metastasis; nodal tumor burden; lymph nodes;
D O I
10.1245/ASO.2002.03.079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The objective of this study was to investigate the relationship between nodal tumor burden and the outcomes of recurrence and survival in sentinel node-positive melanoma patients. Methods: We reviewed a series of sentinel node-positive patients with primary cutaneous melanoma treated with completion lymph node dissection (CLND). Microscopic nodal tumor deposits were counted and measured with an ocular micrometer. Various measures of tumor burden and traditional melanoma prognostic indicators were studied in multivariate Cox regression models. Results: Sentinel lymph node and CLND specimens were evaluated in 90 node-positive patients. The diameter of the largest lymph node tumor nodule and the total lymph node tumor volume were significant predictors of recurrence (two-sided P < .0001 for both) and survival (two-sided P = .0018 and P = .0002, respectively). A tumor deposit diameter of 3 mm was identified as the most significant cut point predictive of recurrence (P < .0001; hazard ratio, 5.18) and survival (P < .0001; hazard ratio, 5.43). The 3-year survival probability was .86 for patients with largest tumor deposit diameters of : 3 mm and was .27 for patients with largest deposit diameters >3 mm (P < .0001). Conclusions: Microstaging of melanoma sentinel lymph node/CLND specimens by using the diameter of the largest tumor deposit is a highly significant predictor of early relapse and survival.
引用
收藏
页码:975 / 981
页数:7
相关论文
共 15 条
[1]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[2]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[3]   AXILLARY DISSECTION IN MELANOMA - PROGNOSTIC VARIABLES IN NODE-POSITIVE PATIENTS [J].
BEVILACQUA, RG ;
COIT, DG ;
ROGATKO, A ;
YOUNES, RN ;
BRENNAN, MF .
ANNALS OF SURGERY, 1990, 212 (02) :125-131
[4]   PROGNOSTIC VALUE OF SIZE OF LYMPH-NODE METASTASES IN PATIENTS WITH CUTANEOUS MELANOMA [J].
BUZAID, AC ;
TINOCO, LA ;
JENDIROBA, D ;
TU, ZN ;
LEE, JJ ;
LEGHA, SS ;
ROSS, MI ;
BALCH, CM ;
BENJAMIN, RS .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2361-2368
[5]   PROGNOSTIC FACTORS IN PATIENTS WITH MELANOMA METASTATIC TO AXILLARY OR INGUINAL LYMPH-NODES - A MULTIVARIATE-ANALYSIS [J].
COIT, DG ;
ROGATKO, A ;
BRENNAN, MF .
ANNALS OF SURGERY, 1991, 214 (05) :627-636
[6]  
DREPPER H, 1993, CANCER, V71, P1239, DOI 10.1002/1097-0142(19930215)71:4<1239::AID-CNCR2820710412>3.0.CO
[7]  
2-Q
[8]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[9]   Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes [J].
Joseph, E ;
Brobeil, A ;
Glass, F ;
Glass, J ;
Messina, J ;
DeConti, R ;
Cruse, CW ;
Rapaport, DP ;
Berman, C ;
Fenske, N ;
Reintgen, DS .
ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (02) :119-125
[10]  
MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392